Beclin1及miRNA-130a与HBV相关慢加急性肝衰竭患者预后的相关性

肝脏 ›› 2021, Vol. 26 ›› Issue (2): 125-127.

Beclin1及miRNA-130a与HBV相关慢加急性肝衰竭患者预后的相关性

陈崇高, 符厚萱, 王小智, 谢会忠

571900 海南澄迈县人民医院重症医学科(陈崇高,符厚萱);海南医学院第二附属医院重症医学科(王小智),消化内科(谢会忠)

收稿日期:2020-05-01 出版日期:2021-02-28 发布日期:2021-03-28
基金资助:
海南省卫生厅科研项目(1801032054A2010)

Beclin1 and miRNA-130a expression correlated with the prognosis of patients with HBV-related acute-on-chronic liver failure

CHEN Chong-gao¹, FU Hou-xuan¹, WANG Xiao-zhi², XIE Hui-zhong³

1. Department of critical medicine, Chengmai County People's Hospital, Chengmai, Hainan, 571900;
2. Department of critical medicine, the Second Affiliated Hospital of Hainan Medical College, Haikou, Hainan, 570100;
3. Department of Gastroenterology, the Second Affiliated Hospital of Hainan Medical College, Haikou, Hainan, 570100

Received:2020-05-01 Online:2021-02-28 Published:2021-03-28

摘要/Abstract

摘要： 目的探讨自噬相关蛋白(Beclin1)及miRNA-130a与乙型肝炎病毒(HBV)相关慢加急性肝衰竭(HBV-ACLF)患者预后的相关性。方法回顾性分析2016年8月至2019年8月收治的132例HBV-ACLF患者的临床资料,根据患者入院治疗6个月的生存情况,将患者分为生存组(65例)和死亡组(67例),并选取同期入院的62例健康体检者为正常对照组。检测三组血清Beclin1及miRNA-130a水平,并采用受试者操作特征(ROC)曲线分析二者对HBV-ACLF患者预后的诊断价值。结果死亡组血清Beclin1显著高于生存组及正常对照组(P<0.05),生存组血清Beclin1显著高于正常对照组(P<0.05);死亡组和生存组血清miRNA-130a表达显著高于正常对照组(P<0.05),而死亡组血清miRNA-130a表达显著低于生存组(P<0.05)。经ROC曲线分析,发现血清Beclin1及miRNA-130a对HBV-ACLF患者预后均有一定诊断价值,曲线下面积分别为0.811、0.836,敏感度分别为0.791、0.851,特异度分别为0.800、0.815。结论血清Beclin1及miRNA-130a与HBV-ACLF患者预后密切相关,临床应引起足够重视。

Abstract: Objective To explore the correlation between the autophagy-related protein (Beclin1) and miRNA-130a and the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF).Methods The clinical data of 132 HBV-ACLF patients were retrospectively analyzed. They were divided into a survival group (65 cases) and a death group (67 cases) according to the survival status after admission for 6 months. 62 healthy people were selected as the normal control group during the same period of time. Serum Beclin1 and miRNA-130a levels were detected in all people in three groups. Receiver operating characteristics (ROC) curves were used to analyze the diagnostic value of these two parameters for HBV-ACLF patients. Results The serum level of Beclin1 in the death group was significantly higher than that in the survival group and the normal control group (P<0.05), and the serum level of Beclin1 in the survival group was significantly higher than the normal control group (P<0.05). Similarly, the expression of serum miRNA-130a in the death group and survival group was significantly higher than that in the normal control group (P<0.05). However, the expression of serum miRNA-130a in the death group was significantly lower than that in the survival group (P<0.05). According to ROC curve analysis, it was found that Beclin1 and mirna-130a had certain diagnostic value for the prognosis of HBV-ACLF patients. The area under the curve (AUC) was 0.811 and 0.836, the sensitivity was 0.791 and 0.851, and the specificity was 0.800 and 0.815, respectively.Conclusion Serum Beclin1 and miRNA-130a are closely associated with the prognosis of HBV-ACLF patients, which should be further investigated in clinical practice.

Key words: Autophagy-related protein, miRNA-130a, Hepatitis B virus-associated acute-on-chronic liver failure, Prognosis

陈崇高, 符厚萱, 王小智, 谢会忠. Beclin1及miRNA-130a与HBV相关慢加急性肝衰竭患者预后的相关性[J]. 肝脏, 2021, 26(2): 125-127.

CHEN Chong-gao, FU Hou-xuan, WANG Xiao-zhi, XIE Hui-zhong. Beclin1 and miRNA-130a expression correlated with the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. Chinese Hepatolgy, 2021, 26(2): 125-127.

参考文献

[1] 李晨, 朱冰, 吕飒, 等. 乙型肝炎病毒相关慢加急性肝衰竭前期患者诊断标准的探讨. 中华肝脏病杂志, 2018, 26:130-135.
[2] 吴娟, 贾琳, 李元元, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者器官功能衰竭的特点与预后. 中华肝脏病杂志, 2018, 26:737-743.
[3] 王玥, 施晓雷. 自噬在常见肝脏疾病中作用机制的研究进展. 肝胆胰外科杂志, 2019, 31:244-247.
[4] 周岐鸣, 刘洋, 季光, 等. 调节自噬改善非酒精性脂肪性肝病的药物研究进展. 中华中医药学刊, 2018, 36:2463-2467.
[5] Chen X, Zhao M, Huang J, et al. MicroRNA-130a suppresses breast cancer cell migration and invasion by targeting FOSL1 and upregulating ZO-1. J Cell Biochem, 2018, 119:4945-4956.
[6] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 实用器官移植电子杂志, 2013, 1:193-202.
[7] 胡大山, 胡建强, 刘欢, 等. 乙型肝炎病毒相关慢加急性肝衰竭临床特点分析. 肝脏, 2018, 23:897-900.
[8] 刘慧敏, 毛青. 乙型肝炎病毒再激活致慢加急性肝衰竭研究进展. 中华实验和临床病毒学杂志, 2019, 33:108-113.
[9] 梁振国, 王佳洁, 劳晓洁, 等. HBV相关慢加急性肝衰竭患者血清自噬相关蛋白的表达及意义. 广西医学, 2019, 41:1792-1794.
[10] 蒋曦, 宋杰, 朱文兵, 等. 细胞自噬与病毒感染研究进展. 国际免疫学杂志, 2018, 41:654-658.
[11] 苑杰, 江沛, 吕佩源, 等. 细胞自噬与疾病发生发展的关系及作为治疗靶点的研究进展. 医学研究生学报, 2018, 31:88-91.
[12] 刘桐言, 方攀奇, 韩忱成, 等. 肿瘤相关成纤维细胞自噬促进肺腺癌细胞侵袭迁移. 中华实验外科杂志, 2019, 36:1543-1545.
[13] 储小飞, 薛晓蕾, 赵舒怡, 等. 乙肝病毒X蛋白连接蛋白抑制辐射诱导的乳腺癌细胞自噬调节的研究. 中华放射医学与防护杂志, 2016, 36:801-805.
[14] 高飞, 尹纪来, 李浩, 等. HBV相关慢加急性肝衰竭患者血清miRNA-130a表达变化及其与病情严重程度和预后的相关性. 山东医药, 2018, 58:65-67.
[15] 薛扬, 郭宏强. 血清miRNA-130a与HBV相关慢加急性(亚急性)肝衰竭患者预后的相关性分析. 肝脏, 2019, 24:158-160.
[16] 牛连杰, 张雅敏. MicroRNA在肝癌干细胞中的作用研究进展. 中华肝胆外科杂志, 2018, 24:641-644.
[17] Zheng QF, Zhang JY, Wu JS, et al. Upregulation of miRNA-130a represents good prognosis in patients with hbv-related acute-on-chronic liver failure: a prospective study. Medicine, 2016, 95:2639-2645.
[18] 徐磊, 黄琠, 赵怡. MicroRNA-130a调节胃癌细胞SCG7901/DDP的耐药机制研究. 现代肿瘤医学, 2015, 23:1358-1361.